Oryzon Genomics: Taking on epigenetics
Biopharmaceutical company Oryzon Genomics has named Roger Bullock its Chief Medical Officer. He will be responsible for executing the clinical development plan of the epigenetic drugs developed by the company.
ADVERTISEMENT
About Michael Kuhrt
This author has not written his bio yet.
But we are proud to say that Michael Kuhrt contributed 541 entries already.
Entries by Michael Kuhrt
IP Flash: Cost pressure
Small companies and academic institutions develop their assets, in most cases, under budget constraints. Still, they have to meet the expectations of future strategic partners or investors in order to be an attractive option for them and to have a chance to get the product onto the market.
GammaDelta Therapeutics: New at the top
London-based immunotherapy developer GammaDelta Therapeutics has hired Paolo Paoletti as Chief Executive Officer. Paoletti was formerly the first appointed President of GSK Oncology, where he was responsible for the overall oncology business.
Modus Therapeutics: Clinical development pro
Modus Therapeutics AB, a Karolinska Development portfolio company developing treatments for sickle cell disease, has appointed Ellen K. Donnelly as CEO. Donnelly joins from Pfizer, Inc, where she most recently was responsible for Clinical Operations for the Neuroscience and Pain therapeutic area.
EuropaBio: Regulatory experience
The European biotech industry association EuropaBio has named John Brennan as its new Secretary General. The life sciences expert will take over his new position in June.
Bioiberica: A boost to the company
In April, Luis Solera assumes the position of CEO at Barcelona-based biotech Bioiberica. He joins from LIPSA, a leading family business in the oils and fats sector.
Karolinska Development: Changes at the top
Following the resignation of erstwhile CEO Jim Van heusden, Karolinska Development has promoted Viktor Drvota to the position of head of the company. Drvota held the position of Chief Investment Officer before.
e-Therapeutics: Newly in charge
AIM-listed drug discovery company e-Therapeutics plc has a new head. In early April, Raymond Barlow took over as Chief Executive Officer.
A potentially game-changing technology
In December 2016, US biotech company Ionis Pharmaceuticals’ drug Spinraza received regulatory approval in the US. No doubt: the antisense technology behind Spinraza could be the next big thing
Domainex: Navigating the growth
Domainex has a new Executive Chairman: Timo Veromaa has been appointed to the Board of the British drug discovery services company.